Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S ADR (NY: NVO )

123.90 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Apr 15, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 20,242
Open 123.90
Bid (Size) 123.15 (2)
Ask (Size) 123.22 (2)
Prev. Close 123.90
Today's Range 123.90 - 123.90
52wk Range 75.56 - 138.28
Shares Outstanding N/A
Dividend Yield 1.43%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Buyback Bonanza: The Top 7 ETFs to Profit From Corporate Cash Splurges
Profit from corporate cash splurges with these top ETFs targeting buyback strategies. Unlock potential gains in a volatile market. 
Via InvestorPlace
Topics ETFs
Healthcare Stocks Are Lagging With Big Earnings Weeks Ahead
Healthcare stocks disappointed again last week with the XLV down over 3% and up only 1.65 % YTD, in a continued downtrend since March 28. 
Via Talk Markets

Performance

YTD
+21.34%
+21.34%
1 Month
-6.76%
-6.76%
3 Month
+16.50%
+16.50%
6 Month
+22.49%
+22.49%
1 Year
+44.85%
+44.85%

More News

Read More
3 Pharma Stocks That Are Money-Printing Machines in 2024
Via InvestorPlace
Topics Economy
Exposures Economy
If You Invested $1000 In This Stock 5 Years Ago, You Would Have $5,200 Today
Via Benzinga
Check Out What Whales Are Doing With NVO
Via Benzinga
Is NYSE:NVO a Good Fit for Dividend Investing?
Via Chartmill
Novo Nordisk and Ginkgo Bioworks Are Teaming Up. Here's Why That's Bullish for Both Stocks.
Via The Motley Fool
Better Buy: Bristol Myers Squibb or the Vanguard S&P 500 ETF?
Via The Motley Fool
Topics Stocks
Exposures US Equities
Better Growth Play: Merck or The Vanguard Growth Index Fund?
Via The Motley Fool
Novo Nordisk Arms Wegovy to Be a Triple Threat
Via MarketBeat
NYSE:NVO is showing good growth, while it is not too expensive.
Via Chartmill
Viking Therapeutics: Strong Results In Obesity
Via Talk Markets
Nvidia Leads 5 Stocks Near Buy Points As S&P 500 Tests Key Level
Via Investor's Business Daily
Topics Artificial Intelligence Stocks
Exposures Artificial Intelligence US Equities
Novo Nordisk's Dominance In Obesity & Diabetes Drug Market Backed by Strong Pipeline: Analyst Gives Outperform Rating
Via Benzinga
Eli Lilly Suffers Legal Loss For Its Popular Weight Loss/Diabetes Drug In Lawsuit Against Florida Compounding Pharmacy
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Novo Nordisk/Eli Lilly's Weight Loss Drugs Does Not Cause Suicidal Behaviors - After FDA, European Medicines Agency Says
Via Benzinga
Exposures Product Safety
Why Wall Street Got Even More Excited About The Glucose Monitor — And How Dexcom, Abbott Labs Stand To Benefit
Via Investor's Business Daily
7 A-Rated Aggressive Biotech Stocks to Bet On in 2024
Via InvestorPlace
Shed the Fat, Gain the Profits: 3 Weight-Loss Stocks to Own Until 2027
Via InvestorPlace
What's Going On With Ginkgo Bioworks Stock?
Via Benzinga
All-Time High Flyers: 7 Stocks to Buy as the Market Peaks
Via InvestorPlace
3 Obesity Drug Stocks Set to Skyrocket as Demand Goes Wild
Via InvestorPlace
2 Healthcare Stocks to Buy Hand Over Fist in April
Via The Motley Fool
Novo Nordisk's Stock Could Get Another Boost, Thanks to This Huge Development
Via The Motley Fool
Can Altimmune get its GLP-1 Drug to Market Before Cash Rush Out?
Via MarketBeat
Exposures Product Safety
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.